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Review
1)
Electrolyte imbalance in neurologic patients
Electrolyte imbalance is known to be the most frequent
systemic complication in patients with neurologic dis-
eases
1). Most electrolyte imbalances in neurologic patients,
except dysnatremia, show comparable frequency with pa-
tients from other diseases and mainly influenced by medi-
cal conditions or co-morbidities
2). For instance, hypo-
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kalemia is commonly manifested as a mild form combined
with hypochloremic alkalosis and mostly associated with
medical treatment such as diuretics, intravenous fluid, and
iatrogenic hyperventilation. Meanwhile, hyperkalemia is
almost always related to deterioration of renal function
2).
Hyponatremia is the most common electrolyte im-
balance in neurologic patients. It can be affected not only
by the patient’s own medical situation, but by neurologic
disease itself though the disruption of arginine vasopressin
(AVP) regulation
3).
In this review, physiologic regulation of water and so-
dium balance, and characteristic sodium disturbances such
as syndrome of inappropriate secretion of antidiuretic hor-
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The kidney and the brain play a major role in maintaining normal homeostasis of the extracellular fluid
by neuroendocrine regulation of sodium and water balance. Therefore, disturbances of sodium balance are
common in patients with central nervous system (CNS) disorders and clinicians should focus not only on
the CNS lesion, but also on the potentially deleterious complications. Hyponatremia is the most common
and important electrolyte disorder affecting patients with critical neurologic diseases. In these patients, the
maladaptation to hyponatremia by impaired osmoregulation in pathologic lesions of brain may cause more
aggressive cerebral edema and increased intracranial pressure due to hypoosmolality induced by hyponatre-
mia. Furthermore, hyponatremia accompanied by CNS disorders has shown to increase delayed cerebral is-
chemia and mortality rates. Two main pathophysiologies of hyponatremia, excluding iatrogenic causes, are
inappropriate secretion of antidiuretic hormone (SIADH) and cerebral salt wasting (CSW) syndrome.
Differential diagnosis between these two entities can be difficult due to considerable overlap in the laboratory
findings and clinical situations. SIADH is in a volume expanded status due to inappropriately secreted argi-
nine vasopressin (AVP) and requires water restriction. However, CSW syndrome is characterized by renal
sodium wasting mainly due to increased natriuretic peptides resulting in volume depletion and follows appro-
priate secretion of AVP. Therefore, maintenance of volume status and sodium replacement is the mainstay
of treatment in CSW syndrome. In this review, we aimed to describe the regulation of sodium and water
balance, and pathophysiology, diagnosis and treatment of hyponatremia in neurologic patients, especially
focusing on SIADH and CSW syndrome.
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mone (SIADH) and cerebral salt wasting (CSW) syndrome
in neurologic patients will be described.
Physiologic regulation of water and sodium balance
The kidney and the brain, with organ cross talk and in-
teraction, play an important role in maintaining sodium and
water balance
4). AVP, also known as antidiuretic hormone
(ADH), is a peptide hormone which is synthesized as a
precursor prohormone in the supraoptic and paraventricular
nuclei of the hypothalamic magnocellular neurons
5). AVP
is carried by its unique neurophysin from the hypothalamus
to its storage site of axon terminals in the posterior pitui-
tary gland. During the axonal transport, it is cleaved from
the neurophysin and stored as a free form
6).
The secretion of AVP is tightly regulated mainly by ex-
tracellular osmolality detected by osmoreceptors which are
thought to be located in the anteromedial hypothalamus
near the neurohypophyseal cell bodies in the supraoptic
nucleus
7). The secretion of AVP in response to plasma os-
molality is extremely sensitive, and only 1% increase in
osmolality above 280 mOsm/Kg can cause significant rise
in plasma AVP levels, which can activate regulatory sys-
tems for antidiuresis and restore the plasma osmolality to
normal
8). At a plasma osmolality of 295 mOsm/kg, the
plasma AVP level reaches approximately 5 pg/mL and
maximum antidiuresis occurs, reflected by a urine osmo-
lality greater than 800 mOsm/kg
8). In addition to osmotic
regulation, the secretion of AVP is also influenced by
blood pressure and volume status detected by barorecep-
tors. Although the response of AVP to hypovolemia is less
sensitive and does not occur without concomitant decrease
in blood pressure, excess amount of AVP is secreted and
acts as a potent vasoconstrictor on the vascular smooth
muscle cells during the hypovolemic or vasodilatory
shock
9). Angiotensin II also have shown to induce AVP
release in some animal studies via angiotensin II type 1
receptors in the lamina terminalis, located in the anterior
wall of the third ventricle
10). Nausea is another potent non-
osmotic factor triggering the secretion of AVP to increase
the plasma level by 20 to 500 fold even if the nausea is
short-lived and unaccompanied by vomiting or changes in
blood pressure
7). After secretion, AVP circulates as a free
form peptide, diffuses readily into the extracellular fluid
space, and is metabolized within minutes by vasopressinase
in the kidney and liver
11).
AVP is an effective agonist to all vasopressin receptor
isoforms: V1a, V1b, and V2 receptor (V2R). The anti-
diuretic effect of AVP is mediated by V2R expressed on
the basolateral membrane of principal cells in the collect-
ing tubule and epithelial cells of the thick ascending loop
of Henle
12). Binding of AVP to V2R in these cells activates
adenylate cyclase, which in turn increases cytosolic cyclic
adenosine monophosphate (cAMP) and cAMP mediated
activation of protein kinase A (PKA). Subsequently, acti-
vation of PKA results in phosphorylation of aquaporin 2
(AQP2) and its translocation from intracellular vesicle to
the apical membrane of the principal cells of the collecting
tubule
13). As a result, urine flow rate is reduced by in-
creased transepithelial solute free-water reabsorption from
the tubular lumen by this apical localized AQP2 which
increases hydro-osmotic permeability of the tubular cells
(Fig. 1).
Hyponatremia in patients with
neurologic disorders
Hyponatremia defined as serum sodium level less than
135 mEq/L is known to occur in up to 20% of hospitalized
patients
14) and is associated with 1.5 fold higher in-hospital
mortality rate than patients without hyponatremia
15). Hypo-
natremia is more common in patients with neurologic dis-
Fig. 1. Role of arginine vasopressin in the regulation of water
balance. AVP, arginine vasopressin; SON, supraoptic nucleus;
PVN, paraventricular nucleus; V2R, V2 receptor; cAMP, cyclic
adenosine monophosphate; AQP2, aquaporin 2.DK Kim and KW Joo : Hyponatremia in Patients with Neurologic Disorders 53
orders than in the general in-hospital population
16) and the
incidence is reported to be 34% of patients with aneur-
ysmal subarachnoid hemorrhage (SAH)
17) and more than
70% in tuberculous meningitis
18). The prevalence of hypo-
natremia developed after transsphenoidal pituitary surgery
for tumor resection may range between 25% and 35%
19,
20).
In the presence of hypoosmolality by hyponatremia, wa-
ter gain causes cerebral edema. Soon after this osmotic
insult, the restoration of brain volume occurs through the
adaptation mechanisms of brain cell, also known as
‘osmoregulation’, by losing the electrolytes and organic os-
molytes
21). However, patients with neurologic diseases may
be more vulnerable to cerebral edema due to impaired os-
moregulation in pathologic lesions of the brain
22). Thus,
these patients can exhibit more aggressive cerebral edema
with deterioration of both clinical status and intracranial
pressure than hyponatremic patients without brain le-
sions
22). Furthermore, hyponatremia accompanied by cen-
tral nervous system (CNS) disorders actually has shown
to increase delayed cerebral ischemia and mortality rates
23).
Although many etiologies such as diuretics, gastro-
intestinal salt loss, hypotonic solutions, and various co-
morbid conditions may cause hyponatremia, two main
mechanisms of hyponatremia, SIADH and CSW syndrome,
account for most of the hyponatremia in patients with neu-
rologic diseases and is directly related to disruption of or-
gan interaction between the brain and kidney
24). Differen-
tial diagnosis between these two disease entities can be
difficult due to considerable overlap in the laboratory find-
ings and clinical situation.
SIADH in patients with neurologic diseases
SIADH is volume expanded status due to increased renal
water reabsorption by excessive and inappropriate AVP se-
cretion in the absence of hyperosmolality or volume deple-
tion
25). In addition, downward resetting of the osmotic
threshold for thirst in these patients is known to be im-
plicated in the development of volume expansion
26).
However, these patients do not show overt hypervolemic
signs, because only one-third of the fluid remains in ex-
tracellular space. Nevertheless, increased glomerular filtra-
tion rate induced by this modest intravascular volume ex-
pansion lead to decreased proximal sodium reabsorption
and increase urinary sodium excretion
27). This sodium
wasting accompanied with water retention often lead to
an equilibrated state of sodium and water balance due to
the vasopressin escape phenomenon
28). Such normal renal
sodium handling despite hyponatremia is a characteristic
feature of SIADH. Serum levels of uric acid and urea nitro-
gen which co-transported with sodium in the proximal tu-
bule are also decreased with increased sodium excretion,
and return to normal value with correction of hyponatremia
in patients with SIADH
27, 28).
The diagnosis of SIADH is usually made from history,
physical examination, and suitable laboratory tests. The di-
agnostic criteria
29) for SIADH is summarized in Table 1.
SIADH is associated with various neurologic diseases
and neurosurgical procedures including encephalitis, men-
ingitis, traumatic brain injury, brain tumors and trans-
Table 1. Diagnostic Criteria for SIADH
Essential feature
Decreased effective osmolality (<275 mOsm/kg of water)
Urinary osmolality >100 mOsm/kg of water during hypo-
tonicity
Clinical euvolemia
No clinical signs of volume depletion of extracellular fluid
No orthostasis, tachycardia, decreased skin turgor, or dry
mucous membranes
No clinical signs of excessive volume of extracellular fluid
No edema or ascites
Urinary sodium >40 mEq/L with normal dietary salt intake
Normal thyroid and adrenal function
No recent use of diuretic agents
Supplemental feature
Plasma uric acid <4 mg/dL
Blood urea nitrogen <10 mg/dL
Fractional sodium excretion >1%; fractional urea excretion
>55%
Failure to correct hyponatremia after 0.9% saline infusion
Correction of hyponatremia through fluid restriction
Abnormal result on test of water load (<80% excretion of
20 mL of water per kilogram of body weight over a
period of 4 hours), or inadequate urinary dilution (<100
mOsm/kg of water)
Elevated plasma AVP levels, despite the presence of
hypotonicity and clinical euvolemia
SIADH, syndrome of inappropriate secretion of antidiuretic
hormone; AVP, arginine vasopressin.54 Electrolyte Blood Press 7:51-57, 2009
sphenoidal pituitary surgery (Table 2)
30). The stimulation
of AVP release from the neurohypophysis in these diseases
may be the possible mechanism for SIADH except some
neuroendocrine tumors with ectopic AVP secretion
31).
The treatment of hyponatremia in patients with SIADH
should be guided by the severity of the disorder, onset
and symptoms of hyponatremia
32). Fluid restriction is the
mainstay of therapy in patients with asymptomatic hypo-
natremia. Although patients with severe neurologic symp-
toms due to acute reductions in serum sodium, require rap-
id initial correction with hypertonic saline, excessively rap-
id correction should be avoided because it can lead to late
onset of neurologic complications from osmotic demyeli-
nation
29, 33).
The AVP receptor antagonist represents more targeted
therapy to the treatment of hyponatremia in SIADH, and
may be potentially beneficial for the treatment of hypona-
tremia in patients with SIADH secondary to neurologic dis-
eases
34). However, the exclusion of CSW syndrome
through careful assessment of volume status and strict
monitoring of serum sodium during treatment will be need-
ed to avoid complications.
CSW syndrome in patients with
neurologic diseases
Many neurosurgical patients with hyponatremia, who
meet the diagnostic criteria for SIADH, have a volume sta-
tus incompatible with that diagnosis. The evidence of vol-
ume depletion and negative sodium balance estimated by
mass balance for urinary electrolytes in these patients is
more consistent with the diagnosis of CSW syndrome
24).
CSW syndrome, which is frequently followed by SAH, is
characterized by excess renal sodium wasting with result-
ing volume depression
35). Although, the mechanism of
CSW syndrome is not fully understood, the most possible
hypothesis is central amplification of natriuretic peptides,
especially brain natriuretic peptide (BNP), combined with
decreased sympathetic outflow due to various neurologic
Table 2. Neurologic Diseases Commonly Associated with SIADH
Encephalitis (viral or bacterial) Cavernous sinus thrombosis
Meningitis (viral, bacterial, tuberculosis, fungal) Neonatal hypoxia
Traumatic brain injury Hydrocephalus
Brain abscess Delirium tremens
Brain tumors Cerebrovascular accident
Guillain-Barré syndrome Acute psychosis
Acute intermittent porphyria Peripheral neuropathy
Subarachnoid hemorrhage Multiple sclerosis
Subdural hematoma Any kind of surgery, most notably transsphenoidal pituitary surgery
Cerebellar and cerebral atrophy
SIADH, syndrome of inappropriate secretion of antidiuretic hormone.
Brain
Kidney
Sympathetic outflow↓
Natriuretic peptides↑ 
(especially BNP)
Proximal Sodium reabsorption↓
RAS inactivation
Vasorelaxant: GFR↑
IMCT Sodium reabsorption↓
AVP antagonism: water reabsorption ↓
• Natriuresis
• Volume depletion
• Appropriate AVP secretion 
Fig. 2. Pathophysiology of cerebral salt wasting syndrome. BNP, brain natriuretic peptide;
RAS, rennin angiotensin system; AVP, Arginine vasopressin; GFR, glomerular filtration
rate; IMCT, inner medullary collecting tubule.DK Kim and KW Joo : Hyponatremia in Patients with Neurologic Disorders 55
diseases
36, 37) (Fig. 2). Since the sympathetic tone in the
kidney plays an important role in proximal sodium and
water handling and the control of renin release in juxtaglo-
merular epithelioid cells
38), decreased sympathetic input in-
to the kidney induces urinary sodium wasting and volume
depletion. In addition, natriuretic peptides stimulate dilata-
tion of afferent renal arterioles and constriction of efferent
arterioles, leading to an increased glomerular filtration
rate
39). These peptides can also act on renal tubules, sup-
pressing angiotensin II stimulated sodium and water trans-
port, inhibiting sodium transporter in the inner medullary
collecting tubules, antagonizing the renal effects of AVP
and reducing sympathetic tone
24, 40). Once volume deple-
tion occurs due to renal sodium wasting, it activates baror-
eceptors that increase AVP release appropriately, resulting
in increased water conservation. Therefore, most patients
with CSW syndrome show elevated AVP levels and meet
the criteria of SIADH. Nevertheless, distinguishing be-
tween CSW syndrome and SIADH should be emphasized
since the adequate treatment regimen is quite different
from each other
23). Although, these disorders are commonly
associated with neurologic diseases and there may be over-
lapping laboratory findings, volume status tends to be nor-
mal or slightly increased in SIADH, whereas decreased in
CSW syndrome. Thus, the evidences of volume depletion
such as weight loss, negative fluid balance, orthostatic hy-
potension and tachycardia in a hyponatremic patient with
neurologic disease are strongly suggestive of CSW syn-
drome
27). In addition, laboratory findings reflecting hemo-
concentration such as elevated hematocrit, albumin, bicar-
bonate and urea nitrogen levels can provide further support
for that diagnosis
36). However, uric acid, which is usually
elevated in patients with volume depletion, tends to be un-
expectedly low in these patients
41). As noted above, hypo-
uricemia due to increased urate excretion also existed in
patients with SIADH. But, the correction of serum sodium
concentration usually leads to normalization of uric acid
levels in patients with SIADH. On the other hand, hypour-
icemia persists after the correction of hyponatremia in pa-
tients with CSW syndrome, possibly due to prolonged
proximal tubule dysfunction
28, 42). Table 3 shows differ-
ential clinical features and diagnosis of CSW syndrome
and SIADH.
In patients with CSW syndrome, the cornerstone of
treatment is achieving euvolemia through vigorous volume
resuscitation with intravenous saline and correcting hypo-
tonicity with sodium replacement
24, 27). Administration of
mineralocorticoid agents which increases sodium re-
absorption in renal tubules can also be considered in cases
refractory to salt and fluid therapy
43). As noted above, vol-
ume restriction following erroneous diagnosis of SIADH
in patients with CSW syndrome can potentially aggravate
hyponatremia. Thus, careful assessment of volume status
in patients is needed to differentiate these diseases.
Summary
Hyponatremia is the most common electrolyte im-
balance in patients with neurologic disease. SIADH and
CSW syndrome are two main mechanisms of hyponatremia
in these patients, excluding iatrogenic causes. Distinction
between the diseases may be difficult due to overlapping
laboratory findings and clinical presentations, but have crit-
ical importance since the adequate therapy is quite different
each other and erroneous diagnosis can lead to grave prog-
nosis as well as aggravation of hyponatremia. The funda-
mental differences between the diseases are the appropri-
ateness of increased AVP release and presence of dysfunc-
tional renal sodium handling. SIADH is in a volume ex-
panded status due to inappropriately secreted AVP and wa-
ter restriction is the treatment of choice. However, CSW
syndrome is in a volume depleted status characterized by
Table 3. Differential Diagnosis of CSW Syndrome and
SIADH
CSW syndrome SIADH
Extracellular volume ↓ / ↔ ↑
Sodium balance Negative Neutral
Hematocrit ↑ ↔
Albumin ↑ ↔
Urea nitrogen ↑ / ↓ ↔
Bicarbonate ↑ / ↔ ↓
Potassium / ↔ ↑ ↔
Uric acid / ↓ ↔ ↓
CSW, cerebral salt wasting; SIADH, syndrome of inappro-
priate secretion of antidiuretic hormone.56 Electrolyte Blood Press 7:51-57, 2009
renal sodium wasting and appropriate secretion of AVP,
requiring volume resuscitation combined with sodium
replacement. Thus, physicians should focus on the volume
status of hyponatremic patients with neurologic disease to
differentiate between these two diseases.
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